title: Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy.
abstract: OBJECTIVE
  •To evaluate the effect of preoperative cisplatin-based chemotherapy on the regional lymph nodes of patients with bladder cancer who attain pathological T0 status in the bladder after chemotherapy followed by radical cystectomy.
  
  
  METHODS
  •Patients who underwent radical cystectomy at MSKCC for urothelial carcinoma of the bladder were retrospectively reviewed. •Those patients achieving pT0 status after preoperative chemotherapy were identified and classified into two groups, those rendered pT0: (i) after receiving neoadjuvant chemotherapy and (ii) after receiving definitive chemotherapy (defined in this case as chemotherapy given for unresectable or regionally metastatic disease). •These two groups were analyzed separately for lymph node status at cystectomy and regional lymph node recurrence.
  
  
  RESULTS
  •Of 169 pT0 patients, 24 patients (14%) had received neoadjuvant chemotherapy, whereas 17 patients (10%) had received definitive chemotherapy for unresectable or regionally metastatic disease. •No patient rendered pT0 after neoadjuvant chemotherapy had lymph node involvement at radical cystectomy or recurrence within the regional lymph node template. •Among patients with advanced disease rendered pT0 by definitive chemotherapy, 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.
  
  
  CONCLUSIONS
  •Patients achieving pT0 status after receiving neoadjuvant chemotherapy had no evidence of lymph node involvement at cystectomy. •Patients undergoing definitive chemotherapy for advanced disease followed by cystectomy experienced reduced rates of nodal involvement compared to the lymph node-positive rates predicted by preoperative clinical staging. However, there remains a risk of regional lymph node involvement in this group.
authors.affiliation: Department of Surgery, Urology Section, Memorial Sloan-Kettering Cancer Center, 1275 York Ave Box 213, New York, NY 10065, USA.
authors.forename: Matthew G
authors.initials: MG
authors.lastname: Kaag
authors.forename: Matthew I
authors.initials: MI
authors.lastname: Milowsky
authors.forename: Guido
authors.initials: G
authors.lastname: Dalbagni
authors.forename: R Houston
authors.initials: RH
authors.lastname: Thompson
authors.forename: Darren
authors.initials: D
authors.lastname: Katz
authors.forename: Victor E
authors.initials: VE
authors.lastname: Reuter
authors.forename: Harry W
authors.initials: HW
authors.lastname: Herr
authors.forename: Dean
authors.initials: D
authors.lastname: Bajorin
authors.forename: Bernard H
authors.initials: BH
authors.lastname: Bochner
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D015653:Cystectomy; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*